Ongoing clinical trials are evaluating a new immunotherapeutic approach for the treatment of malignant melanoma–the combination of an oncolytic virus with checkpoint inhibition.
Sigrid Eckardt, PhD
Advertisement
Articles by Sigrid Eckardt, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
3
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
4
Investigating Novel Immunotherapy Targets in Metastatic RCC
5